Blevins L S, Verity D K, Allen G
Department of Neurosurgery, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Oncology (Williston Park). 1998 Sep;12(9):1307-12, 1315; discussion 1315-8.
Although almost all pituitary tumors are benign adenomas, a surprisingly large number of these tumors invade tissues outside of the pituitary gland. Such invasion, by itself, is not diagnostic of pituitary carcinomas, which are exceedingly rare (0.13% of 2,342 pituitary tumors in one series). Several different criteria are available to determine whether a tumor is invasive. Intraoperative biopsies demonstrate an 85% incidence of microscopic invasion of the dura. Evidence of gross invasion at surgery and radiologic evidence of invasion on magnetic resonance imaging (MRI) and computed tomographic (CT) scans occur at a much lower incidence but may be more predictive of surgical cure. Invasive adenomas also have higher proliferation rates than do noninvasive adenomas, as shown by immunohistochemical detection of proliferating cell nuclear antigen (PCNA), Ki-67, and MIB-1. The expression of p53, increased epidermal growth factor receptors, and protein kinase C activity also correlate with invasion and aggressive behavior. Clinically significant invasion is more frequent with macroadenomas. Macroadenomas of all pituitary tumor subtypes except gonadotroph macroadenomas have a greater than 50% incidence of gross invasion. Currently, there is no accepted means of predicting an adenoma's clinically significant invasiveness and long-term aggressiveness.
尽管几乎所有垂体肿瘤都是良性腺瘤,但其中有相当数量的肿瘤会侵犯垂体腺以外的组织。这种侵犯本身并不能诊断为垂体癌,垂体癌极为罕见(在一组2342例垂体肿瘤中占0.13%)。有几种不同的标准可用于确定肿瘤是否具有侵袭性。术中活检显示硬脑膜微观侵犯的发生率为85%。手术中肉眼可见的侵犯证据以及磁共振成像(MRI)和计算机断层扫描(CT)上的影像学侵犯证据发生率要低得多,但可能更能预测手术治愈情况。如通过免疫组化检测增殖细胞核抗原(PCNA)、Ki-67和MIB-1所示,侵袭性腺瘤的增殖率也高于非侵袭性腺瘤。p53的表达、表皮生长因子受体增加以及蛋白激酶C活性也与侵袭和侵袭性行为相关。临床上显著的侵犯在大腺瘤中更为常见。除促性腺激素细胞大腺瘤外,所有垂体肿瘤亚型的大腺瘤肉眼可见侵犯的发生率均超过50%。目前,尚无公认的方法来预测腺瘤临床上显著的侵袭性和长期侵袭性行为。